Standard Chemical & Pharmaceutical Co Ltd (1720) - Total Liabilities
Based on the latest financial reports, Standard Chemical & Pharmaceutical Co Ltd (1720) has total liabilities worth NT$2.60 Billion TWD (≈ $81.98 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Standard Chemical & Pharmaceutical Co Lt strategic investment ratio to see how much of total assets are deployed in long-term investments.
Standard Chemical & Pharmaceutical Co Ltd - Total Liabilities Trend (2002–2024)
This chart illustrates how Standard Chemical & Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see balance sheet size of Standard Chemical & Pharmaceutical Co Lt.
Standard Chemical & Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Standard Chemical & Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Galectin Therapeutics Inc
NASDAQ:GALT
|
USA | $146.00 Million |
|
ICBC Turkey Bank AS
IS:ICBCT
|
Turkey | TL93.98 Billion |
|
K&F Growth Acquisition Corp. II Class A Ordinary shares
NASDAQ:KFII
|
USA | $10.15 Million |
|
BridgeBio Oncology Therapeutics, Inc.
NASDAQ:BBOT
|
USA | $45.37 Million |
|
Tongxing Environmental Protection
SHE:003027
|
China | CN¥602.26 Million |
|
Benchmark Metals Inc
V:CEI
|
Canada | CA$40.06 Million |
|
Promotora Ambiental S.A.B. de C.V
MX:PASAB
|
Mexico | MX$5.29 Billion |
|
Sword Group S.E
F:9RS
|
Germany | €227.23 Million |
Liability Composition Analysis (2002–2024)
This chart breaks down Standard Chemical & Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See 1720 net asset quality score to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.41 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.44 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.22 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Standard Chemical & Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Standard Chemical & Pharmaceutical Co Ltd (2002–2024)
The table below shows the annual total liabilities of Standard Chemical & Pharmaceutical Co Ltd from 2002 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | NT$2.20 Billion ≈ $69.30 Million |
-27.92% |
| 2023-12-31 | NT$3.05 Billion ≈ $96.14 Million |
-13.62% |
| 2022-12-31 | NT$3.53 Billion ≈ $111.30 Million |
+6.91% |
| 2021-12-31 | NT$3.30 Billion ≈ $104.11 Million |
+54.15% |
| 2020-12-31 | NT$2.14 Billion ≈ $67.54 Million |
-6.05% |
| 2019-12-31 | NT$2.28 Billion ≈ $71.88 Million |
+4.05% |
| 2018-12-31 | NT$2.19 Billion ≈ $69.09 Million |
+0.96% |
| 2017-12-31 | NT$2.17 Billion ≈ $68.43 Million |
+7.04% |
| 2016-12-31 | NT$2.03 Billion ≈ $63.93 Million |
+6.33% |
| 2015-12-31 | NT$1.91 Billion ≈ $60.12 Million |
+7.88% |
| 2014-12-31 | NT$1.77 Billion ≈ $55.73 Million |
-0.10% |
| 2013-12-31 | NT$1.77 Billion ≈ $55.79 Million |
-2.54% |
| 2012-12-31 | NT$1.82 Billion ≈ $57.24 Million |
+4.17% |
| 2011-12-31 | NT$1.74 Billion ≈ $54.95 Million |
+8.65% |
| 2010-12-31 | NT$1.61 Billion ≈ $50.58 Million |
+55.10% |
| 2009-12-31 | NT$1.04 Billion ≈ $32.61 Million |
+9.71% |
| 2008-12-31 | NT$943.47 Million ≈ $29.72 Million |
+29.84% |
| 2007-12-31 | NT$726.66 Million ≈ $22.89 Million |
-20.31% |
| 2006-12-31 | NT$911.85 Million ≈ $28.73 Million |
-10.28% |
| 2005-12-31 | NT$1.02 Billion ≈ $32.02 Million |
-36.42% |
| 2004-12-31 | NT$1.60 Billion ≈ $50.36 Million |
-1.57% |
| 2003-12-31 | NT$1.62 Billion ≈ $51.17 Million |
+27.36% |
| 2002-12-31 | NT$1.28 Billion ≈ $40.17 Million |
-- |
About Standard Chemical & Pharmaceutical Co Ltd
Standard Chemical & Pharmaceutical Co., Ltd., together with its subsidiaries, manufactures and sells pharmaceutical products in Taiwan and internationally. The company offers Chinese and western medicine, cosmetics, beverage, normal instruments, and medical instruments. It also sells various medical supplements, as well as preventive medicine; and imports and exports various medical products, med… Read more